Search Results - "Damaj, G L"

ROMIDEPSIN PLUS CHOP VERSUS CHOP IN PATIENTS WITH PREVIOUSLY UNTREATED PERIPHERAL T‐CELL LYMPHOMA: FINAL ANALYSIS OF THE RO‐CHOP TRIAL by Camus, V., Thieblemont, C., Gaulard, P., Cheminant, M., Casasnovas, R., Ysebaert, L., Damaj, G. L., Guidez, S., Pica, G. M., Kim, W. S., Lim, S. T., Andre, M., Gutiérrez, N., Penarrubia, M. J., Staber, P. B., Trotman, J., Hüttmann, A., Stefoni, V., Rossi, G., Delfau‐Larue, M., Cottereau, A., Itti, E., Li, J., Delarue, R., Leval, L., Morschhauser, F., Bachy, E.

Get full text

EARLY POSITRON EMISSION TOMOGRAPHY RESPONSE‐ADAPTED TREATMENT IN LOCALIZED DIFFUSE LARGE B‐CELL LYMPHOMA (AAIPI=0) : RESULTS OF THE PHASE 3 LYSA LNH 09‐1B TRIAL by Bologna, S, Vander Borght, T, Briere, J, Ribrag, V, Damaj, G. L, Thieblemont, C, Feugier, P, Peyrade, F, Lebras, L, Coso, D, Sibon, D, Bonnet, C, Morschhauser, F, Ghesquieres, H, Becker, S, Olivier, P, Fabiani, B, Tilly, H, Haioun, C, Bastie, J. N

Get full text

OUTCOMES AFTER FIRST‐LINE IMMUNOCHEMOTHERAPY FOR PRIMARY MEDIASTINAL B CELL LYMPHOMA PATIENTS: A LYSA STUDY by Camus, V., Rossi, C., Sesques, P., Lequesne, J., Tonnelet, D., Haioun, C., Durot, E., Willaume, A., Gauthier, M., Moles‐Moreau, Marie‐P., Antier, C., Lazarovici, J., Monjanel, H., Bernard, S., Tardy, M., Besson, C., Lebras, L., Choquet, S., Le Du, K., Bonnet, C., Bailly, S., Damaj, G.‐L., Laribi, K., Maisonneuve, H., Houot, R., Chauchet, A., Jardin, F., Traverse‐Glehen, A., Decazes, P., Becker, S., Berriolo‐Riedinger, A., Tilly, H.

Get full text

P1239: TISLELIZUMAB, A PD‐1 INHIBITOR FOR RELAPSED/REFRACTORY MATURE T‐ AND NK‐CELL NEOPLASMS: RESULTS FROM A PHASE 2 STUDY by Bachy, E., Savage, K. J., Huang, H., Kwong, Y. L., Gritti, G., Zhang, Q., Liberati, A. M., Cao, J., Yang, H., Hao, S., Hu, J., Zhou, K., Russo, F., Zhang, H., Sang, W., Ji, J., Ferreri, A. J. M., Damaj, G. L., Liu, H., Zhang, W., Ke, X., Ghiggi, C., Huang, S., Li, X., Yao, H., Paik, J., Novotny, W., Zhou, W., Zhu, H., Huang, J., Zinzani, P. L.

Get full text

P1133: SUB‐CUTANEOUS RITUXIMAB INDUCTION FOLLOWED BY SHORT RITUXIMAB MAINTENANCE IMPROVES PFS IN PATIENTS WITH LOW‐TUMOR BURDEN FOLLICULAR LYMPHOMA. FINAL RESULTS OF FLIRT PHASE III TRIAL, A LYSA STUDY by Cartron, G., Bachy, E., Tilly, H., Daguindau, N., Pica, G.‐M., Bijou, F., Mounier, C., Clavert, A. M., Damaj, G. L., Slama, B., Casasnovas, O., Houot, R., Bouabdallah, K., Sibon, D., Fitoussi, O., Morineau, N., Herbaux, C., Gastinne, T., Fornecker, L.‐M., Haioun, C., Launay, V., Araujo, C., Benbrahim, O., Sanhes, L., Gressin, R., Gonzalez, H., Morschhauser, F., Xerri, L., Tarte, K., Pranger, D.

Get full text

Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial by Morschhauser, Franck, Tilly, Hervé, Chaidos, Aristeidis, McKay, Pamela, Phillips, Tycel, Assouline, Sarit, Batlevi, Connie Lee, Campbell, Phillip, Ribrag, Vincent, Damaj, Gandhi Laurent, Dickinson, Michael, Jurczak, Wojciech, Kazmierczak, Maciej, Opat, Stephen, Radford, John, Schmitt, Anna, Yang, Jay, Whalen, Jennifer, Agarwal, Shefali, Adib, Deyaa, Salles, Gilles

“…Activating mutations of EZH2, an epigenetic regulator, are present in approximately 20% of patients with follicular lymphoma. We investigated the activity and…”
Get full text

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023 by Camus, V, Thieblemont, C, Gaulard, P, Cheminant, M, Casasnovas, R, Ysebaert, L, Damaj, G L, Guidez, S, Pica, G M, Kim, W S, Lim, S T, Andre, M, Gutiérrez, N, Penarrubia, M J, Staber, P B, Trotman, J, Hüttmann, A, Stefoni, V, Rossi, G, Delfau-Larue, M, Cottereau, A, Itti, E, Li, J, Delarue, R, de Leval, L, Morschhauser, F, Bachy, E

Get full text

THIOTEPA BUSULFAN CYCLOPHOSPHAMIDE, A TOXIC CONDITIONING FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CENTRAL NERVOUS SYSTEM LYMPHOMA: REMISSION OR INFECTION? by Debureaux, P-E, Royer, B., Gruson, B., Votte, P., Joris, M., Damaj, G. L., Marolleau, J-P, Delphine, L.

Get full text

FIRST‐LINE THERAPY OF T‐CELL LYMPHOMA: ALLOGENEIC OR AUTOLOGOUS TRANSPLANTATION FOR CONSOLIDATION ‐ FINAL RESULTS OF THE AATT STUDY by Tournilhac, O., Truemper, L., Ziepert, M., Bouabdallah, K., Nickelsen, M., Maury, S., Reimer, P., Jaccard, A., Herr, W., Wilhelm, M., Cartron, G., Wulf, G., Sanhes, L., Dreger, P., Lamy, T., Kroschinsky, F., Lindemann, H., Roussel, M., Viardot, A., Sibon, D., Delmer, A., De Leval, L., Damaj, G.L., Gisselbrecht, C., Gaulard, P., Rosenwald, A., Friedrichs, B., Altmann, B., Schmitz, N.

Get full text

First-line rituximab (R) high-dose therapy (R-HDT) versus R-CHOP14 for young adults with diffuse large B-cell lymphoma: Preliminary results of the GOELAMS 075 prospective multicenter randomized trial by Le Gouill, S., Milpied, N. J., Lamy, T., Delwail, V., Gressin, R., Guyotat, D., Damaj, G. L., Foussard, C., Cartron, G., Maisonneuve, H., Deconinck, E., Dreyfus, F., Gyan, E., Sutton, L., Morineau, N., Alexis, M., Perry, F., Sauvezie, M.

“…Abstract only…”
Get full text